Preclinical safety testing for cell-based products using animals

Biologicals

Volumn 43, Issue 5, 2015, Pages 425-428

  McBlane, James W ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Advanced therapy medicinal products; Cell therapy; Clinical trials; Marketing authorisation; Preclinical testing; Tumourigenicity

Indexed keywords

ABSORPTION; BIOLOGICAL MONITORING; BIOSAFETY; CARCINOGENICITY; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL THERAPY; CELLULAR DISTRIBUTION; CHEMICAL REACTION KINETICS; CONFERENCE PAPER; ELIMINATION REACTION; GENOTOXICITY; HUMAN; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL THERAPY; PATIENT SAFETY;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; HUMANS; PATIENT SAFETY;

EID: 84941314426     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2015.05.002     Document Type: Conference Paper

References (8)

1. Broichhausen C., Riquelme P., Ahrens N., Wege A.K., Koehl G.E., Schlitt H.J., et al. In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies. Mol Ther - Meth Clin Dev 2014, 1:1-12.
2. ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals.
3. ICH S7A note for guidance on safety pharmacology studies for human pharmaceuticals CHMP/ICH/539/00.
4. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18(4):843-851.
5. Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122(6):863-871.
6. Rosenberg S.A. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther 2010, 18(10):1744-1745.
7. WHO evaluation of cell substrates for the production of biological: revision of recommendations 2009, Report of the WHO Study Group on cell substrates for the production of biologicals.
8. Schneider C.K., Salmikangas P., Jilma B., Flamion B., Todorova L.R., Paphitou A., et al. Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 2010, 9:195-201.